L26/P-872 Cumulative doses of clomiphene citrate and risk of fetal death in a cohort study of in vitro fertilization cycles for the United States, 2004-2021
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1196 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Davies und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Is the cumulative clomiphene citrate (CC) dose across cycles associated with increased risk for fetal death among fresh autologous in vitro fertilization (IVF) cycles? Summary answer Rates of spontaneous abortion, stillbirth, and multiple birth increased linearly as cumulative clomiphene citrate dose increased. What is known already We, and others, have published work showing CC is related to multiple pregnancy, prematurity, birth defects & perinatal death (NEJM, PLOSOne, JCEM). We have repeated these observations experimentally in a dose-dependent way within a murine model (Endocrinology) thereby demonstrating a causal relationship. Generalizing this result to humans nevertheless remains fraught. So, demonstrating a dose response relationship between CC and fetal death within a clinical infertility population greatly reduces the risk of confounding by indication, whilst replicating the murine model. Observing a dose-response relationship will thereby place us one step closer to understanding ovulation induction by CC and adverse pregnancy outcomes. Study design, size, duration We conducted a population cohort study of 21,004 fresh, autologous IVF embryo transfer cycles that were performed in US fertility clinics between 2004 and 2021 and used clomiphene citrate for ovulation induction. We considered total clomiphene citrate doses >2000 milligrams (mg) to be outliers and excluded those cycles from analysis (n = 280). Frozen cycles were not available. Participants/materials, setting, methods We created 4 categories of total clomiphene dosage (<500mg, 500-749mg, 750-999mg, and ≥1000mg) and used robust Poisson regression models to estimate risk ratios (aRR) and 95% confidence intervals (CI) for the association between dose and biochemical pregnancy, clinical intrauterine pregnancy, spontaneous abortion, stillbirth, live birth, multiple birth, and preterm delivery. Models adjusted for age, parity, prior assisted reproductive technology cycles, infertility diagnosis, race/ethnicity, and body mass index (BMI). Race/ethnicity and BMI were multiply imputed. Main results and the role of chance The median total clomiphene citrate dose was 500mg, with 4,476 cycles (21.3%) using <500mg, 14,241 (67.8%) using 500-749mg, 1,517 (7.2%) using 750-999mg, and 770 (3.7%) using 1000mg or greater. After adjustment, rates of spontaneous abortion were higher for patients using 500-749mg and 750-999mg of clomiphene citrate, relative to those using <500mg (11.8% vs 10.3%, aRR 1.12, CI 1.02-1.25 and 14.4% vs 10.3%, aRR 1.38, CI 1.18-1.62, respectively). There was a 3-fold increased rate of stillbirth for the ≥1000mg group compared with the <500mg group; however, the estimate was imprecise due to small sample size and the confidence interval included the null (0.7% vs 0.2%, aRR 3.30, CI 0.88-12.39). Multiple birth risk was significantly higher for all clomiphene citrate dosage categories compared with the <500mg group (15.7%): 21.8%, aRR 1.38, CI 1.16-1.64 for the 500-749mg group, 23.8%, aRR 1.47, CI 1.14-1.89 for the 750-999mg group, and 28.3%, aRR 1.47, CI 1.25-2.22 for the ≥1000mg group. No significant effects were observed for the other outcomes of interest. Limitations, reasons for caution Our study was limited to fresh embryo transfer cycles, and we could not evaluate outcomes in frozen embryo transfer cycles. Sample size for some outcomes was modest, resulting in imprecise estimates at extreme doses. Independent replication with greater statistical power is indicated. Wider implications of the findings Our findings highlight, firstly, the need to further assess causality in fertility treatments and adverse outcomes. Secondly, we need to examine sources of variability in patient response to clomiphene citrate to inform individualized dosing strategies to avoid multiple births and adverse outcomes. Trial registration number No
Zitieren
APA
Davies, M., & Boulet, S. (2026). L26/P-872 Cumulative doses of clomiphene citrate and risk of fetal death in a cohort study of in vitro fertilization cycles for the United States, 2004-2021. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1196
Vancouver
Davies M, Boulet S. L26/P-872 Cumulative doses of clomiphene citrate and risk of fetal death in a cohort study of in vitro fertilization cycles for the United States, 2004-2021. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1196
BibTeX
@article{Davies2026,
author = {Davies, M. and Boulet, S.},
title = {L26/P-872 Cumulative doses of clomiphene citrate and risk of fetal death in a cohort study of in vitro fertilization cycles for the United States, 2004-2021},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1196}
}
EUVIMED